Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial
Abstract
1. Introduction
2. Methods
2.1. Patients
2.2. Study Design
2.3. Anesthetic Management
2.4. Data Collection
2.5. Statistical Analysis
3. Results
3.1. Patients
3.2. Demographic and Perioperative Characteristics
3.3. Inflammatory Indices: IL-6, CRP
3.4. Hemodynamics: MAP, HR, SVV, CI, Temperature
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Glehen, O.; Mohamed, F.; Gilly, F.N. Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004, 5, 219–228. [Google Scholar] [CrossRef]
- Yan, T.D.; Welch, L.; Black, D.; Sugarbaker, P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 2007, 18, 827–834. [Google Scholar] [CrossRef]
- Sugarbaker, P.H. Peritonectomy procedures. Surg. Oncol. Clin. N. Am. 2003, 12, 703–727. [Google Scholar] [CrossRef]
- Capone, A.; Valle, M.; Proietti, F.; Federici, O.; Garofalo, A.; Petrosillo, N. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J. Surg. Oncol. 2007, 96, 507–513. [Google Scholar] [CrossRef] [PubMed]
- Ceelen, W.P.; Flessner, M.F. Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nat. Rev. Clin. Oncol. 2010, 7, 108–115. [Google Scholar] [CrossRef] [PubMed]
- Kajdi, M.-E.; Beck-Schimmer, B.; Held, U.; Kofmehl, R.; Lehmann, K.; Ganter, M.T. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Retrospective analysis of a single centre three-year experience. World J. Surg. Oncol. 2014, 12, 136. [Google Scholar] [CrossRef]
- Coccolini, F.; Corbella, D.; Finazzi, P.; Brambillasca, P.; Benigni, A.; Prussiani, V.; Ceresoli, M.; Manfredi, R.; Poiasina, E.; Bertoli, P.; et al. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy. Minerva Anestesiol. 2016, 82, 310–319. [Google Scholar]
- Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef]
- Bhana, N.; Goa, K.L.; McClellan, K.J. Dexmedetomidine. Drugs 2000, 59, 263–268; discussion 269–270. [Google Scholar] [CrossRef]
- Talke, P.; Chen, R.; Thomas, B.; Aggarwall, A.; Gottlieb, A.; Thorborg, P.; Heard, S.; Cheung, A.; Son, S.L.; Kallio, A. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth. Analg. 2000, 90, 834–839. [Google Scholar] [CrossRef]
- Jiang, L.; Hu, M.; Lu, Y.; Cao, Y.; Chang, Y.; Dai, Z. The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis. J. Clin. Anesth. 2017, 40, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Wu, M.; Xu, J.; Wu, C.; Zhang, B.; Wang, G.; Ma, D. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: Systematic review and meta-analysis. Br. J. Anaesth. 2019, 123, 777–794. [Google Scholar] [CrossRef] [PubMed]
- Dong, W.; Chen, M.H.; Yang, Y.H.; Zhang, X.; Huang, M.J.; Yang, X.J.; Wang, H.Z. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 3510–3515. [Google Scholar] [PubMed]
- Ueki, M.; Kawasaki, T.; Habe, K.; Hamada, K.; Kawasaki, C.; Sata, T. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia 2014, 69, 693–700. [Google Scholar] [CrossRef]
- Bulow, N.M.; Colpo, E.; Pereira, R.P.; Correa, E.F.; Waczuk, E.P.; Duarte, M.F.; Rocha, J.B. Dexmedetomidine decreases the inflammatory response to myocardial surgery under mini-cardiopulmonary bypass. Braz. J. Med. Biol. Res. 2016, 49, e4646. [Google Scholar] [CrossRef][Green Version]
- Yu, H.; Dong, R.; Lu, Y.; Yang, X.; Chen, C.; Zhang, Z.; Peng, M. Short-term postoperative cognitive dysfunction and inflammatory response in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A pilot study. Mediat. Inflamm. 2017, 2017, 3605350. [Google Scholar] [CrossRef] [PubMed]
- Desborough, J.P. The stress response to trauma and surgery. Br. J. Anaesth. 2000, 85, 109–117. [Google Scholar] [CrossRef]
- Kim, N.Y.; Yoo, Y.C.; Park, H.; Choi, Y.D.; Kim, C.Y.; Bai, S.J. The effect of dexmedetomidine on intraocular pressure increase in patients during robot-assisted laparoscopic radical prostatectomy in the steep trendelenburg position. J. Endourol. 2015, 29, 310–316. [Google Scholar] [CrossRef]
- Kim, M.H.; Yoo, Y.C.; Bai, S.J.; Lee, K.Y.; Kim, N.; Lee, K.Y. Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J. Int. Med. Res. 2021, 49, 300060520983263. [Google Scholar] [CrossRef]
- Kohl, B.A.; Deutschman, C.S. The inflammatory response to surgery and trauma. Curr. Opin. Crit. Care 2006, 12, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Gouin, J.-P.; Kiecolt-Glaser, J.K. The impact of psychological stress on wound healing: Methods and mechanisms. Crit. Care Nurs. Clin. N. Am. 2012, 24, 201–213. [Google Scholar] [CrossRef]
- Sun, Y.B.; Zhao, H.; Mu, D.L.; Zhang, W.; Cui, J.; Wu, L.; Alam, A.; Wang, D.X.; Ma, D. Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis. Cell Death Dis. 2019, 10, 167. [Google Scholar] [CrossRef]
- Cui, J.; Zhao, H.; Yi, B.; Zeng, J.; Lu, K.; Ma, D. Dexmedetomidine attenuates bilirubin-induced lung alveolar epithelial cell death in vitro and in vivo. Crit. Care Med. 2015, 43, e356–e368. [Google Scholar] [CrossRef]
- Gu, J.; Sun, P.; Zhao, H.; Watts, H.R.; Sanders, R.D.; Terrando, N.; Xia, P.; Maze, M.; Ma, D. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit. Care 2011, 15, R153. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Davies, R.; Ma, D. Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU. Br. J. Anaesth. 2021, 126, e33–e35. [Google Scholar] [CrossRef]
- Taniguchi, T.; Kidani, Y.; Kanakura, H.; Takemoto, Y.; Yamamoto, K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit. Care Med. 2004, 32, 1322–1326. [Google Scholar] [CrossRef]
- Kawasaki, T.; Kawasaki, C.; Ueki, M.; Hamada, K.; Habe, K.; Sata, T. Dexmedetomidine suppresses proinflammatory mediator production in human whole blood in vitro. J. Trauma Acute Care Surg. 2013, 74, 1370–1375. [Google Scholar] [CrossRef]
- Li, B.; Li, Y.; Tian, S.; Wang, H.; Wu, H.; Zhang, A.; Gao, C. Anti-inflammatory effects of perioperative dexmedetomidine administered as an adjunct to general anesthesia: A meta-analysis. Sci. Rep. 2015, 5, 12342. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.; Zhao, J.; Zheng, L.; Jing, S.; Wang, X. Effect of dexmedetomidine on perioperative stress response and immune function in patients with tumors. Technol. Cancer Res. Treat. 2020, 19, 1533033820977542. [Google Scholar] [CrossRef]
- Veenhof, A.A.; Sietses, C.; von Blomberg, B.M.; van Hoogstraten, I.M.; vd Pas, M.H.; Meijerink, W.J.; vd Peet, D.L.; vd Tol, M.P.; Bonjer, H.J.; Cuesta, M.A. The surgical stress response and postoperative immune function after laparoscopic or conventional total mesorectal excision in rectal cancer: A randomized trial. Int. J. Colorectal Dis. 2011, 26, 53–59. [Google Scholar] [CrossRef] [PubMed]
- McCarthy, L.; Wetzel, M.; Sliker, J.K.; Eisenstein, T.K.; Rogers, T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001, 62, 111–123. [Google Scholar] [CrossRef]
- Póvoa, P. C-reactive protein: A valuable marker of sepsis. Intensive Care Med. 2002, 28, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Nijsten, M.W.; Olinga, P.; The, T.H.; de Vries, E.G.; Koops, H.S.; Groothuis, G.M.; Limburg, P.C.; ten Duis, H.J.; Moshage, H.; Hoekstra, H.J.; et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit. Care Med. 2000, 28, 458–461. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xu, X.; Liu, H.; Ji, F. Effects of dexmedetomidine on patients undergoing radical gastrectomy. J. Surg. Res. 2015, 194, 147–153. [Google Scholar] [CrossRef]
- Wang, K.; Li, C. Effects of dexmedetomidine on inflammatory factors, t lymphocyte subsets and expression of nf-kappab in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma. Oncol. Lett. 2018, 15, 7153–7157. [Google Scholar]
- Walker, S.M.; Howard, R.F.; Keay, K.A.; Fitzgerald, M. Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in rat pups. Anesthesiology 2005, 102, 1226–1234. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.W.; Shahzad, M.M.; Lin, Y.G.; Armaiz-Pena, G.; Mangala, L.S.; Han, H.D.; Kim, H.S.; Nam, E.J.; Jennings, N.B.; Halder, J.; et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin. Cancer Res. 2009, 15, 2695–2702. [Google Scholar] [CrossRef]
- Horowitz, M.; Neeman, E.; Sharon, E.; Ben-Eliyahu, S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 2015, 12, 213–226. [Google Scholar] [CrossRef]
- Gertler, R.; Brown, H.C.; Mitchell, D.H.; Silvius, E.N. Dexmedetomidine: A novel sedative-analgesic agent. In Baylor University Medical Center Proceedings; Taylor & Francis: Abingdon, UK, 2001; Volume 14, pp. 13–21. [Google Scholar]
- Jalonen, J.; Hynynen, M.; Kuitunen, A.; Heikkilä, H.; Perttilä, J.; Salmenperä, M.; Valtonen, M.; Aantaa, R.; Kallio, A. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology 1997, 86, 331–345. [Google Scholar] [CrossRef] [PubMed]
Variables | Control Group (n = 22) | Dexmedetomidine Group (n = 23) | p-Value |
---|---|---|---|
Age, years | 59.5 ± 13.0 | 53.4 ± 12.7 | 0.121 |
Female, n | 18 (82%) | 15 (65%) | 0.208 |
Body mass index, kg/m2 | 23.6 ± 3.7 | 23.9 ± 3.1 | 0.779 |
ASA physical status | 0.767 | ||
II | 12 (52%) | 13 (57%) | |
III | 10 (48%) | 10 (43%) | |
Hypertension | 8 (36%) | 5 (22%) | 0.279 |
Diabetes mellitus | 1 (5%) | 1 (4%) | >0.999 |
Cancer origin | 0.260 | ||
Colon origin | 15 (68%) | 19 (83%) | |
OBGY origin | 7 (32%) | 4 (17%) | |
PCI score | 11.6 ± 5.6 | 12.6 ± 8.8 | 0.685 |
Complete cytoreduction | 18 (82%) | 22 (96%) | 0.187 |
Variables | Control Group (n = 22) | Dexmedetomidine Group (n = 23) | p-Value |
---|---|---|---|
Intraoperative variables | |||
Anesthesia time, min | 636 ± 208 | 635 ± 208 | 0.984 |
Operation time, min | 580 ± 205 | 581 ± 208 | 0.995 |
Intraoperative crystalloid, mL | 5044 ± 2601 | 5920 ± 5345 | 0.487 |
Intraoperative colloid, mL | 1089 ± 361 | 1152 ± 236 | 0.486 |
Transfused RBC, pack | 2.0 ± 3.2 | 1.6 ± 2.1 | 0.594 |
Urine output, mL | 1297 ± 879 | 1503 ± 849 | 0.429 |
Blood loss, mL | 893 ± 778 | 873 ± 948 | 0.938 |
Total RI, unit | 5.4 ± 7.1 | 4.9 ± 4.9 | 0.787 |
Intraoperative LEVO, µg/kg | 22.1 ± 21.7 | 22.4 ± 20.3 | 0.962 |
Co-operation | 16 (73%) | 17 (74%) | 0.928 |
Postoperative ventilator care | 5 (23%) | 5 (22%) | >0.999 |
Postoperative hospital stays, days | 16 ± 11 | 16 ± 11 | 0.988 |
Follow up duration, days | 573 ± 193 | 496 ± 209 | 0.207 |
Postoperative complication | |||
Pneumonia | 1 (5%) | 1 (4%) | >0.999 |
AKI | 0 (0%) | 0 (0%) | >0.999 |
Ileus | 5 (23%) | 6 (26%) | 0.793 |
Obstruction | 0 (0%) | 0 (0%) | >0.999 |
Rebleeding | 1 (5%) | 0 (0%) | 0.489 |
Reoperation | 0 0%) | 1 (4%) | >0.999 |
Perforation | 0 0%) | 1 (4%) | >0.999 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moon, J.; Yoo, Y.C.; Kim, M.H.; Jeon, S.; Joo, H.J.; Chun, D.-H.; Kim, N.Y. Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial. J. Clin. Med. 2021, 10, 3145. https://doi.org/10.3390/jcm10143145
Moon J, Yoo YC, Kim MH, Jeon S, Joo HJ, Chun D-H, Kim NY. Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial. Journal of Clinical Medicine. 2021; 10(14):3145. https://doi.org/10.3390/jcm10143145
Chicago/Turabian StyleMoon, Jiae, Young Chul Yoo, Myoung Hwa Kim, Soyoung Jeon, Hye Ji Joo, Duk-Hee Chun, and Na Young Kim. 2021. "Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial" Journal of Clinical Medicine 10, no. 14: 3145. https://doi.org/10.3390/jcm10143145
APA StyleMoon, J., Yoo, Y. C., Kim, M. H., Jeon, S., Joo, H. J., Chun, D.-H., & Kim, N. Y. (2021). Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial. Journal of Clinical Medicine, 10(14), 3145. https://doi.org/10.3390/jcm10143145